Tumor Biology

, Volume 36, Issue 4, pp 2249–2255 | Cite as

RETRACTED ARTICLE: Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics

  • Youwei Kou
  • Lei Qiao
  • Qiang Wang
Research Article


We aimed to identify the potential microRNA (miRNA) targets for colorectal cancer (CRC). Small RNA-seq and RNA-seq data of GSE46622 were downloaded from Gene Expression Omnibus (GEO) database, including samples of tumor tissue, metastasis tissue, and normal tissue from eight CRC patients. Data comparison of small RNA-seq and RNA-seq was performed through Bowtie and TopHat softwares, respectively. Then the expressed values of each sample were calculated by Cufflinks and Cuffdiff based on fragments per kilobase of exon per millionfragments mapped (FPKM) methods. The differentially expressed miRNAs and core miRNAs were identified by paired t-test. Besides, miRNA target genes were integrated through miRanda, MirTarget2, PicTar, PITI, TargetScan, and miRecords databases, followed by functional analysis of specific miRNA. The average comparison rate of sequence reads in miRNA, noncoding RNA, and other areas of the genome is 49.75, 2.90, and 47.35 %, respectively. A total of 49 miRNAs was differentially expressed. Compared with normal controls, 3 miRNAs were upregulated and 13 miRNAs were downregulated in tumor samples as well as 48 miRNAs were upregulated and 20 miRNAs were downregulated in the metastasis samples. Among them, 18 metastasis-specific expressed miRNAs, 2 tumor-specific expressed miRNAs, and 11 normal expressed miRNA were found. miRNA-1, miRNA-338-5p, miRNA-326, and miR-490-5p were selected as important miRNAs. Besides, miRNA-338-5p target gene RAB6B, FAP, and CTGF were identified as oncogenes. The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment.


RNA-seq MicroRNAs Molecular mechanism 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA. 2008;300(23):2765–78.CrossRefPubMedGoogle Scholar
  3. 3.
    Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One. 2011;6(6):6.Google Scholar
  4. 4.
    Kontou N, Psaltopoulou T, Soupos N, Polychronopoulos E, Xinopoulos D, Linos A, et al. Alcohol consumption and colorectal cancer in a Mediterranean population: a case-control study. Dis Colon Rectum. 2012;55(6):703–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS. Adverse events after screening and follow-up colonoscopy. Cancer Causes Control. 2012;23(2):289–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Chan SK, Griffith OL, Tai IT, Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev. 2008;17(3):543–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang GJ, Li Y, Zhou H, Xiao HX, Zhou T. miR20a is an independent prognostic factor in colorectal cancer and is involved in cell metastasis. Mol Med Rep. 2014;10(1):283–91.PubMedGoogle Scholar
  12. 12.
    Valeri N, Braconi C, Gasparini P, Hart J, Grivennikov S, Lovat F, et al. microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer. Lancet. 2013;381:S17.CrossRefGoogle Scholar
  13. 13.
    Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36.CrossRefPubMedGoogle Scholar
  14. 14.
    Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Rohr C, Kerick M, Fischer A, Kuhn A, Kashofer K, Timmermann B et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One. 2013;8(7)Google Scholar
  16. 16.
    Burge SW, Daub J, Eberhardt R, Tate J, Barquist L, Nawrocki EP et al. Rfam 11.0: 10 years of RNA families. Nucleic Acids Res. 2013;41(database issue):3Google Scholar
  17. 17.
    Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):30Google Scholar
  18. 18.
    Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):2009–10.CrossRefGoogle Scholar
  19. 19.
    Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–11.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schee K, Lorenz S, Worren MM, Gunther CC, Holden M, Hovig E et al. Deep sequencing the microRNA transcriptome in colorectal cancer. PLoS One. 2013;8(6)Google Scholar
  22. 22.
    Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res. 2013;41(Database issue):12Google Scholar
  23. 23.
    Chen JS, Hung WS, Chan HH, Tsai SJ, Sun HS. In silico identification of oncogenic potential of FYN-related kinase in hepatocellular carcinoma. Bioinformatics. 2013;29(4):420–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2012;18(3):737–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012;10(4):504–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, et al. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Cancer Res. 2011;71(17):5646–58.CrossRefPubMedGoogle Scholar
  27. 27.
    Röhr C, Kerick M, Fischer A, Kühn A, Kashofer K, Timmermann B, et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One. 2013;8(7):e67461.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Albasri A, Al-Ghamdi S, Fadhil W, Aleskandarany M, Liao YC, Jackson D, et al. Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene. 2011;30(26):2997–3002.CrossRefPubMedGoogle Scholar
  29. 29.
    Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013;13(280):1471–2407.Google Scholar
  30. 30.
    Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol. 2014;44(1):13–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299(4):425–36.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ju Y-cH J-A, Lan S-H, Wang T-H, Lin P-C, Lee J-C, Niu K-C, et al. Characterization of a colorectal cancer migration and autophagy-related microRNA miR-338-5p and its target gene PIK3C3. Genomic Medicine, Biomarkers, and Health Sciences. 2012;4(1):19–20.CrossRefGoogle Scholar
  33. 33.
    Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci. 2008;15(6):675–85.CrossRefPubMedGoogle Scholar
  34. 34.
    Lin BR, Chang CC, Chen RJ, Jeng YM, Liang JT, Lee PH, et al. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 2011;17(10):3077–88.CrossRefPubMedGoogle Scholar
  35. 35.
    Sun Z, Yang P, Liang LY, Zhang T, Zhang WJ, Cao J. [Expression of connective tissue growth factor in colorectal cancer and its association with prognosis]. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(11):1166–70.PubMedGoogle Scholar
  36. 36.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.CrossRefPubMedGoogle Scholar
  37. 37.
    Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics. 2009;6(5):281–95.PubMedGoogle Scholar
  38. 38.
    Ting WC, Chen LM, Pao JB, Yang YP, You BJ, Chang TY, et al. Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci. 2013;10(8):1022–7.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 2008;146(1):32–42.CrossRefPubMedGoogle Scholar
  40. 40.
    van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol. 2010;101(3):259–69.PubMedGoogle Scholar
  41. 41.
    Xu E, Xia X, Lu B, Xing X, Huang Q, Ma Y, et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog. 2007;46(11):924–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Elander N, Soderkvist P, Fransen K. Matrix metalloproteinase (MMP)-1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006;26(1B):791–5.PubMedGoogle Scholar
  43. 43.
    Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007;22(7):1064–70.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Gastrointestinal and Nutriology SurgeryShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Colorectal Surgery and OncologyShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations